CJC-1295 / Ipamorelin Blend

This blend combines a GHRH-receptor agonist material with a ghrelin-receptor agonist. The commercial combination itself has limited formal research.

The intended research concept is dual stimulation of pituitary growth-hormone release through complementary GHRH and GHS-R pathways.

Blend-level evidence is limited or unestablished.

Blend, No established blend evidence

Exact CJC-1295 identity is critical, and individual endocrine studies do not establish mixture pharmacology or safety.

Potential concerns include endocrine dysregulation, glucose changes, edema, cardiovascular effects, and immunogenicity.

No FDA-approved combination drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.